Table 1.
Clinical and Biochemical Data of The Cohort at Inclusion, First Follow‐Up, and Second Follow‐Up
| Inclusion (n = 129) | 1st Follow‐Up (n = 88) | 2nd Follow‐Up (n = 59) | |
|---|---|---|---|
| Age (years) | 51.0 ± 12.9 | 61.0 ± 11.0 | 66.3 ± 10.3 |
| Sex (male) | 87 (67%) | 62 (70%) | 47 (81%) |
| BMI (kg/m2) | 28.3 ± 3.8 | 29.1 ± 4.7 | 29.1 ± 4.0 |
| Overweight | 72 (56%) | 49 (56%) | 25 (42%) |
| Obese | 37 (29%) | 29 (33%) | 24 (41%) |
| Previously diagnosed diabetes | 11 (8.5%) | 6 (6.8%) | 3 (5.1%) |
| Diabetes/IGT diagnosed at first follow‐up | NA | 69 (78%) | 42 (71%) |
| Diabetes/IGT diagnosed at second follow‐up | NA | NA | 47 (80%) |
| Hypertensive | 93 (72%) | 83 (94%) | 55 (93%) |
| Manifest cardiovascular disease | 14 (11%) | 16 (18%) | 17 (29%) |
| Hypertriglyceridemia | 74 (57%) | 35 (40%) | 39 (66%) |
| Metabolic syndrome | NA | 70 (80%) | 51 (86%) |
| ALT (U/L) | 76 ± 43 | 60 ± 35 | 50 ± 34 |
| AST (U/L) | 45 ± 23 | 35 ± 15 | 42 ± 23 |
| AST/ALT ratio | 0.6 ± 0.2 | 0.7 ± 0.3 | 0.9 ± 0.4 |
| ALP (U/L) | 61 ± 33 | 65 ± 37 | 72 ± 31 |
| Bilirubin (mg/dL) | 0.64 ± 0.30 | 0.78 ± 0.33 | 0.8 ± 0.8 |
| Albumin (g/dL) | 4.1 ± 0.3 | 4.2 ± 0.4 | 4.0 ± 0.4 |
| Platelet count ( × 109/L) | 235 ± 67 | 194 ± 94 | 222 ± 57 |
| Prothrombin (INR) | 1.0 ± 0.1 | 1.0 ± 0.2 | 1.1 ± 0.4 |
| Ferritin (μg/L) | 232 ± 317 | 192 ± 159 | 257 ± 230 |
| Glucose (mg/dL) | NA | 125 ± 38 | 135 ± 45 |
| IR HOMA | NA | 3.8 ± 3.5 | 9.6 ± 13 |
| Triglycerides (mg/dL) | 190 ± 134 | 157 ± 89 | 170 ± 109 |
| Cholesterol (mg/dL) | 236 ± 59 | 202 ± 43 | 178 ± 53 |
| HDL (mg/dL) | NA | 51 ± 19 | 48 ± 16 |
| LDL (mg/dL) | NA | 123 ± 37 | 100 ± 44 |
| Negative for HBsAg/ anti‐HCV | NA | 88/88 | 59/59 |
| Negative for HBV DNA/HCV RNA | NA/NA | 88/88 | 59/59 |
| Positive for transglutaminase antibodies | NA | 0 (0%) | 1 (1.7%) |
| Mutation in HFE gene: | |||
| C282Y homozygosity/C282Y heterozygosity | NA | 2/6 | 1/3 |
| H63D homozygosity/H63D heterozygosity | NA | 3/16 | 1/10 |
| S65C homozygosity/S65C heterozygosity | NA | 0/2 | 0/2 |
| C282Y/H63D compound heterozygosity | NA | 0 | 0 |
| Mutation in SERPINA1 gene (ZZ/ SZ/ MZ/ MS) | NA | 0/0/10/3 | 0/0/8/0 |
| Ceruloplasmin < 0.20 g/L | 0 (0%) | 0 (0%) | 1 (1.7%) |
Abbreviations: ALP, alkaline phosphatase; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HDL, high‐density lipoprotein; IGT, impaired glucose tolerance; INR, international normalized ratio; IRHOMA, insulin resistance according to homeostasis model assessment; LDL, low‐density lipoprotein; NA, not available.